Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

@article{Palou2018RecurrencePA,
  title={Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought},
  author={Juan Palou and Francesca Pisano and Richard Sylvester and Steven Joniau and Vincenzo Serretta and St{\'e}phane Larr{\'e} and Stephanie Di Stasi and Bas W. G. van Rhijn and Alfred J Witjes and Andr{\'e} J. A. Grotenhuis and R. Colombo and Alberto Briganti and Marko Babjuk and Viktor Soukup and P. U. Malmstrom and Jacques Irani and N{\'u}ria Malats and Jack Baniel and R. D. P. Mano and Tommaso Cai and Eugene K Cha and Peter Uwe Ardelt and John M Varkarakis and Riccardo Bartoletti and Guido Dalbagni and Shahrokh F Shariat and Evanguelos Xylinas and Robert Jeffrey Karnes and Paulo Gontero},
  journal={World Journal of Urology},
  year={2018},
  pages={1-7}
}
The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have… CONTINUE READING